GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients

Journal of Korean Medical Science

Volumn 25, Issue 1, 2010, Pages 110-116

  Park, Hyun Jung ^a   Koo, Young Ah ^a   Im, Young Hyuck ^a   Yoon, Byung Koo ^a   Choi, DooSeok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Breast neoplasms; Drug Therapy; GnRH agonist; Ovarian function

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLLITROPIN; GONADORELIN; LEUPRORELIN; LUTEINIZING HORMONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; MENSTRUATION; MULTIMODALITY CANCER THERAPY; OVARIAN FUNCTION TEST; PREMATURE OVARIAN FAILURE; SOUTH KOREA; TIME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; LUTEINIZING HORMONE; MENSTRUATION; OVARIAN FAILURE, PREMATURE; OVARIAN FUNCTION TESTS; REPUBLIC OF KOREA; TAMOXIFEN; TIME FACTORS;

EID: 77949329430     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.1.110     Document Type: Article

References (19)

1. Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003; 4: 251-4.
2. Ataya K., Moghissi K. Chemotherapy-induced premature ovarian failure: mechanisms and prevention. Steroids 1989; 54: 607-26.
3. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620-6.
4. Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, Di Noto A, Contreras Ortiz O, Pavlovsky S. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001; 81: 391-7.
5. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Rea S. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006; 106: 514-23.
6. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes or ovaries. Oncologist 2007; 12: 1044-54.
7. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-70.
8. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA 1979; 242: 1877-81.
9. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premeno-pausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29.
10. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
11. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994;68:105-10.
12. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-72.
13. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 1999; 6: 229-39.
14. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophos-phamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1997; 39: 1403-9.
15. Nabholtz J, Peinkowski T, Mackey J. Phase III trial comparing TAC with RAC in the adjuvant treatment of node positive breast cancer patients:interim analysis of the BCIRG001 study. Pro Am Soc Clin Oncol 2002; 21: 36a.
16. Kil WJ, Ahn SD, Shin SS, Lee WS, Choi EK, Kim JH, Son BH, Ahn SH, Kim WK, Kim SB. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients. Breast Cancer Res Treat 2006; 96: 245-50.
17. Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T, Hill C, Tursz T. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16: 389-96.
18. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-31.
19. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Invesig 2001; 8: S60-4.